Aggressive Surgery for Pancreatic Neuroendocrine Tumors Abstract #766

Introduction: The role of surgery for advanced pancreatic neuroendocrine tumor (pNET) requiring extended resections is not well-defined.
Aim(s): To clarify whether aggressive surgical approach influenced long-term results and to identifiy survival prognostic factors in light of the 2010 WHO classification.
Materials and methods: Between 01/2000 and 03/2012, 37 patients with pNET underwent pancreatic resection alone (Group I:27 patients) or associated to extended resection (Group II:10 patients). All tumors were reclassified according to the 2010 WHO classification.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Nadia Russolillo

To read results and conclusion, please login ...

Further abstracts you may be interested in

#3069 Functioning Pancreatic Neuroendocrine Tumors (F-pNETs): The Experience of a Tertiary Care Center of Pancreatic Surgery
Introduction: Surgery represents the optimal treatment of F-pNETs, especially if performed in high volume centers of pancreatic surgery.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Chiara Nessi
Authors: Nessi C, Lenzi S, Landoni L, Bianchi B, ...
#3048 Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors
Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: PhD Giovanni Schinzari
#701 High Expression of Mammalian Target of Rapamycin (mTOR) in NF1-Related Periampullary Neuroendocrine Tumors
Introduction: Neurofibromatosis type 1 (NF1) is a rare inherited disorder associated with cutaneous lesions and neoplasms in the nervous and gastroenteropancreatic systems, including periampullary NETs. NF1-coded protein, neurofibromin, is a tumor suppressor that negatively regulates the mammalian target of rapamycin (mTOR). Preclinical in vitro and in vivo studies demonstrated a constitutive activation of mTOR pathway associated with significant antineoplastic effects of mTOR inhibitors in NF1-related glial tumor models.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Surgical treatment
Presenting Author: MD Paola Razzore
#769 Surgicial Management of Gastroenteropancreatic Neuroendocrine Tumors: Early and Long-Term Results
Introduction: Surgery could improve survival of gastroenteropancreatic neuroendocrine tumors (GEP NET). Nevertheless, data on survival prognostic factors come from studies focusing on heterogeneous population including both resected and non-resected patients.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Surgical treatment
Presenting Author: Nadia Russolillo
Keywords: GEP-NET, surgery
#2957 New Evidence of Emerging Nodal Metastasis in Staging System after Surgical pNET Resection as Predictive Factor for Recurrence. Result from Monocentric Retrospective Series
Introduction: New evidence is emerging of the role of pNETs lymphatic metastasis in terms of Oncological Outcomes. A specific staging classification is not actually available.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Laura Mastrangelo